Joint pain and inflammation affect millions of Americans, driving demand for supplements that actually deliver measurable relief. That’s why we conducted this Kre-Celazine inflammation study—a double-blind, placebo-controlled trial published in the Journal of the American Nutraceutical Association. The results showed a significant reduction in site-specific arthritis pain, particularly in hands, wrists, and neck, offering brands a clinically validated ingredient for joint health formulations.
A Single-Center, Double-Blind Placebo Controlled Study to Evaluate the Efficacy of Kre-Celazine®, an Oral Buffered Creatine-Cetylated Fatty Acid Compound, in its Ability to Reduce Site-specific Inflammation and Pain
Jeff Golini, Margaret Beeson, N.D., Deborah Angersbach, N.D., Jeff Moore, N.D., Patricia Holl, D.C., Chrissy Amicone, N.D., Wendy L. Jones, MS
All American Pharmaceutical; Yellowstone Naturopathic Clinic, Billings, Montana; Royal Knight Incorporated, Rochester, Minnesota
Published in the Journal of the American Nutraceutical Association (JANA) – Volume 12, No. 1, 2009
Background
Immune-related joint degenerative conditions are expected to strike more than 27 million Americans during the next decade. It is the primary reason for doctor visits and increased health care costs. As the population ages, the demand for safe, effective, non-pharmaceutical interventions continues to grow—making clinically validated ingredients like Kre-Celazine® increasingly valuable for brands serving this market.
Cetylated fatty acids have been reported to exhibit an anti-inflammatory activity in joint/muscle and ligament regions in animal studies. These unique compounds are thought to work by integrating into cell membranes, improving flexibility and reducing the inflammatory cascade that leads to pain and stiffness.
In cell culture studies, creatine monohydrate can modulate certain aspects of cell-surface/pro-inflammatory reactant interactions.
Creatine is used by athletes engaged in high-energy, ergogenic, and supportive functions. Until recently, very little attention has been paid to its ability to modulate cell-surface interactions. This mechanism suggests that combining creatine with cetylated fatty acids could offer complementary benefits—addressing both the energy needs of stressed tissues and the inflammatory response itself.
Study Objective
Determine whether an oral, alkali–buffered creatine–cetylated fatty acid compound was capable of reducing site-specific arthritis with its chronic joint and muscle-related inflammation and pain.
Participants and Method
A total of 35 subjects (21 males, 14 females), ranging in ages 23 to 88, experiencing at least one area of chronic, localized joint/tissue pain and stiffness, underwent an extensive pre-screening process to confirm a diagnosis of arthritis. This broad age range was intentional—designed to assess efficacy across different stages of joint health, from early onset to more advanced degenerative conditions.
Volunteers were divided into two groups: ‘Group A’ (n = 24) received 3 grams of Kre-Celazine® daily (4 capsules in all), and ‘Group B’ (n = 11) received the same number of capsules of a placebo daily, for 30 days. In addition, participants were required to complete a weekly pain journal and comply with blood draw and examination schedules, as per the protocol. The pain journal provided qualitative data that complemented the objective clinical measurements, offering a complete picture of each participant’s experience.
Results
(Detailed numbers can be seen by clicking the Research Poster Presentation image below)
Summary
Our findings indicate that Kre-Celazine® is the most effective in reducing arthritis pain and stiffness in the extremities, including the hand, wrist, and elbow, as well as the neck and shoulder regions. These results are particularly encouraging because these areas often respond poorly to conventional treatments.
Research Poster Presentation Image:
